Literature DB >> 32020531

An Update on Population Pharmacokinetic Analyses of Vancomycin, Part I: In Adults.

Abdullah Aljutayli1, Amélie Marsot2,3,4, Fahima Nekka1,5,6.   

Abstract

Despite the wide clinical use of vancomycin, controversy remains regarding its optimal dosage regimens. This can be attributed to the large between- and within-subject variability in the pharmacokinetics of vancomycin. This review aimed at providing a synthesis of population pharmacokinetic models of vancomycin in adults, determining the most reported pharmacokinetic models, and identifying various sources of variability in different special subpopulations to better inform vancomycin dosing. We searched PubMed and EMBASE for population pharmacokinetic studies of vancomycin published from January 2011 to May 2019. Inspection of the relevant lists of references was conducted, as well. This search resulted in a total of 30 eligible studies, which were included. One-, two-, and three-compartments models were reported to best describe vancomycin population pharmacokinetics in 13, 14, and 3 studies, respectively. Three-compartment models were implemented in three studies to account for an additional cerebrospinal fluid compartment. The most common predictors were creatinine clearance and bodyweight, in 20 and 13 studies, respectively. Estimated values of vancomycin clearance and total volume of distribution varied widely from 0.334 to 8.75 L/h (0.0054-0.1279 L/h/kg) and from 7.12 to 501.8 L (0.097-6.97 L/kg), respectively. Almost all studies implemented an exponential interindividual variability model, and the highest variability on clearance was 99.2%. In conclusion, this review highlights the wide ranges and the high variability of estimated population pharmacokinetic parameters. This information can help guide dosing in different subpopulations. Yet, additional analyses with pooled subpopulations might be needed to confirm the necessity of modified dosage regimens.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32020531     DOI: 10.1007/s40262-020-00866-2

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  48 in total

Review 1.  Vancomycin: a review of population pharmacokinetic analyses.

Authors:  Amélie Marsot; Audrey Boulamery; Bernard Bruguerolle; Nicolas Simon
Journal:  Clin Pharmacokinet       Date:  2012-01-01       Impact factor: 6.447

Review 2.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael Rybak; Ben Lomaestro; John C Rotschafer; Robert Moellering; William Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Am J Health Syst Pharm       Date:  2009-01-01       Impact factor: 2.637

3.  Are vancomycin trough concentrations adequate for optimal dosing?

Authors:  Michael N Neely; Gilmer Youn; Brenda Jones; Roger W Jelliffe; George L Drusano; Keith A Rodvold; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

4.  Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin.

Authors:  Evan J Zasowski; Kyle P Murray; Trang D Trinh; Natalie A Finch; Jason M Pogue; Ryan P Mynatt; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

5.  Making the change to area under the curve-based vancomycin dosing.

Authors:  Emily L Heil; Kimberly C Claeys; Ryan P Mynatt; Teri L Hopkins; Karrine Brade; Ian Watt; Michael J Rybak; Jason M Pogue
Journal:  Am J Health Syst Pharm       Date:  2018-10-17       Impact factor: 2.637

6.  Vancomycin Area Under the Curve and Acute Kidney Injury: A Meta-analysis.

Authors:  Doaa M Aljefri; Sean N Avedissian; Nathaniel J Rhodes; Michael J Postelnick; Kevin Nguyen; Marc H Scheetz
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

7.  Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing.

Authors:  Michael N Neely; Lauren Kato; Gilmer Youn; Lironn Kraler; David Bayard; Michael van Guilder; Alan Schumitzky; Walter Yamada; Brenda Jones; Emi Minejima
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

8.  Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia.

Authors:  Yosuke Suzuki; Kanako Kawasaki; Yuhki Sato; Issei Tokimatsu; Hiroki Itoh; Kazufumi Hiramatsu; Masaharu Takeyama; Jun-Ichi Kadota
Journal:  Chemotherapy       Date:  2012-11-07       Impact factor: 2.544

9.  Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients.

Authors:  Thomas P Lodise; Nimish Patel; Ben M Lomaestro; Keith A Rodvold; George L Drusano
Journal:  Clin Infect Dis       Date:  2009-08-15       Impact factor: 9.079

Review 10.  The Nephrotoxicity of Vancomycin.

Authors:  E J Filippone; W K Kraft; J L Farber
Journal:  Clin Pharmacol Ther       Date:  2017-06-05       Impact factor: 6.875

View more
  14 in total

1.  Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations.

Authors:  Yu Cheng; Chen-Yu Wang; Zi-Ran Li; Yan Pan; Mao-Bai Liu; Zheng Jiao
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

2.  Prospective Cohort Study of Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Adults on Extracorporeal Membrane Oxygenation.

Authors:  Younghee Jung; Dong-Hwan Lee; Hyoung Soo Kim
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

3.  Predicting Antibiotic Effect of Vancomycin Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation: Dense Sampling versus Sparse Sampling.

Authors:  Yong Kyun Kim; Jae Ha Lee; Hang-Jea Jang; Dae Young Zang; Dong-Hwan Lee
Journal:  Antibiotics (Basel)       Date:  2022-05-31

4.  Application of Machine Learning Classification to Improve the Performance of Vancomycin Therapeutic Drug Monitoring.

Authors:  Sooyoung Lee; Moonsik Song; Jongdae Han; Donghwan Lee; Bo-Hyung Kim
Journal:  Pharmaceutics       Date:  2022-05-09       Impact factor: 6.525

Review 5.  Population Pharmacokinetics of Tigecycline: A Systematic Review.

Authors:  Can-Can Zhou; Fang Huang; Jing-Ming Zhang; Yu-Gang Zhuang
Journal:  Drug Des Devel Ther       Date:  2022-06-17       Impact factor: 4.319

6.  Population Pharmacokinetics of Vancomycin in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation (an ASAP ECMO Study).

Authors:  Vesa Cheng; Mohd H Abdul-Aziz; Fay Burrows; Hergen Buscher; Young-Jae Cho; Amanda Corley; Arne Diehl; Eileen Gilder; Stephan M Jakob; Hyung-Sook Kim; Bianca J Levkovich; Sung Yoon Lim; Shay McGuinness; Rachael Parke; Vincent Pellegrino; Yok-Ai Que; Claire Reynolds; Sam Rudham; Steven C Wallis; Susan A Welch; David Zacharias; John F Fraser; Kiran Shekar; Jason A Roberts
Journal:  Antimicrob Agents Chemother       Date:  2021-10-11       Impact factor: 5.938

7.  The Osteogenic Effect of Local Delivery of Vancomycin and Tobramycin on Bone Marrow Stromal Cells.

Authors:  Lingjia Yu; Qi Fei; Jisheng Lin; Yong Yang; Yisheng Xu
Journal:  Infect Drug Resist       Date:  2020-07-01       Impact factor: 4.003

8.  Population Pharmacokinetic Modeling of Vancomycin in Thai Patients With Heterogeneous and Unstable Renal Function.

Authors:  Siriluk Jaisue; Cholatip Pongsakul; David Z D'Argenio; Pakawadee Sermsappasuk
Journal:  Ther Drug Monit       Date:  2020-12       Impact factor: 3.118

9.  The Glomerular Filtration Rate Estimators in the Pharmacokinetic Modelling in Acute Kidney Injury: An Observational Study.

Authors:  Silvijus Abramavicius; Vaidotas Galaune; Agile Tunaityte; Astra Vitkauskiene; Gintautas Gumbrevicius; Aurelija Radzeviciene; Romaldas Maciulaitis
Journal:  Antibiotics (Basel)       Date:  2021-02-04

10.  Vancomycin area under the curves estimated with pharmacokinetic equations using trough-only data.

Authors:  Nathan Fewel
Journal:  J Clin Pharm Ther       Date:  2021-06-25       Impact factor: 2.512

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.